Midgard Science

3billion

Seoul, South Korea 3billion.io

From their website, Nov 2026

Work here? Claim this listing

About

3billion provides rare disease genetic diagnostic services and newborn genetic screening services. It serves patients, families, clinicians, and partners from its site in Seoul, South Korea, with support for customers around the world.

Services

  • 3B-GENOME

    Whole-genome sequencing-based genetic testing for rare disease diagnosis, with automated reanalysis and raw data included.

  • 3B-EXOME

    Exome-focused genetic testing for rare disease diagnosis, with automated reanalysis and raw data included.

  • 3B-VARIANT

    Sanger sequencing to confirm a specific variant in a patient or family member.

  • 3B-INTERPRETER

    Genomic data analysis and interpretation service for user-generated FASTQ data, with a clinical report.

  • GEBRA™

    Variant interpretation and diagnosis platform that turns VCF data into a final clinical report.

  • Reanalysis

    Automatic reanalysis of previously undiagnosed rare disease cases using updated databases, AI, and expert review.

  • Drug discovery

    AI-based drug discovery work for rare diseases, including target discovery, pocket discovery, and compound design.

  • Newborn genetic screening

    Genetic screening services for newborns, as named in the service terms.

  • 3B-NEO

    Newborn genetic screening service.

  • EVIDENCE

    Automated genetic variant interpretation system.

  • 3Cnet

    Variant pathogenicity prediction tool.

Turnaround
Within 4 weeks · Results within 2 weeks · Initial response within one business day · We will respond within 24 business hours · 3B-GENOME & 3B-EXOME results within 4 weeks · EVIDENCE classifies ~100,000 WES variants in 5 minutes on average
What to send
FASTQ data · Blood · Saliva · Other specimens · Sample kit included for ordering · Biological samples such as blood, saliva, or other specimens

Capabilities

Assays and studies
Rare disease genetic testing · Variant interpretation · Reanalysis · Genomic data analysis · Sanger confirmation · Newborn genetic screening · WGS · WES · Pathogenicity prediction
Scale and capacity
70+ countries where testing is available · 2,200+ clinicians who have used their testing · 100,000+ patients who have received test results · 62,000+ patients' genomes tested · 40,000+ patients' genomes tested · 20,000+ patients' genomes tested · 2,200+ clinicians who have used the testing · 12+ global pharma partners
Therapeutic areas
Rare diseases · Reproductive loss · Fetal death · Inherited risk · Orphan drugs

Instruments and platforms

  • Illumina NovaSeq X

Modalities and species

Modalities
Small molecule
Species and models
Human · Illumina NovaSeq X

Certifications

As the company states them, with the certificate or registry record where there is one.

  • CLIASelf-reported

    As listed: CLIA (ID # 99D2274041); CLIA certified

  • CAPSelf-reported

    As listed: CAP (License # 8750906); CAP accredited

Industries served

  • Pharma
  • Rare disease diagnostics

Company

Founded
2016

Locations

Based in
Seoul, South Korea
Sites
Seoul, South Korea
Serves
worldwide, 70+ countries

Contacts

Similar labs

Work here? Claim this listing